Compliance with the new traceability requirements necessitates an understanding of how and when to begin implementing changes in an ever-evolving industry.
The US Court of Appeals granted Amgen’s request to block Novartis’ Neupogen biosimilar, Zarxio, from the US market until the court resolves litigation between the two companies.